| Code | CSB-RA007759MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to docaravimab, targeting ERAL1 (Era-like 12S mitochondrial rRNA chaperone 1). ERAL1 is a mitochondrial GTPase that plays a critical role in mitochondrial ribosome biogenesis, specifically functioning as an RNA chaperone essential for the maturation of the 12S mitochondrial ribosomal RNA. This protein is vital for proper mitochondrial translation and oxidative phosphorylation. Mutations in ERAL1 have been associated with severe mitochondrial disorders, including Perrault syndrome, characterized by sensorineural hearing loss and ovarian dysfunction, as well as other mitochondrial encephalopathies presenting with developmental delays and neurological impairment.
As a biosimilar to docaravimab, this antibody provides researchers with a reliable tool for investigating ERAL1 expression, localization, and function in mitochondrial biology studies. It enables exploration of mitochondrial ribosome assembly mechanisms, mitochondrial disease pathogenesis, and potential therapeutic targets for inherited mitochondrial disorders. This reagent supports investigations into cellular energy metabolism and mitochondrial dysfunction across various experimental contexts.
There are currently no reviews for this product.